Table 2.
Characteristics and comparison of RA subgroups according to anti-CCP antibodies.
| Variable | RA patients | P | |
|---|---|---|---|
| Anti-CCP (−) n = 37 |
Anti-CCP (+) n = 45 |
||
| Age, years ± SD | 41.59 ± 11.41 | 44.09 ± 12.73 | 0.36 |
| Disease duration, years ± SD | 5.44 ± 7.69 | 4.90 ± 6.85 | 0.75 |
| DAS28, units ± SD | 1.43 ± 0.95 | 3.14 ± 0.44 | 0.05 |
| Remission (<2.6) | 19 (51.35) | 16 (33.3) | 0.06 |
| Hands' Steinbrocker stage, III or IV, n (%) | 0 | 7 (15.6) | 0.01 |
| Lipid profile | |||
| TC, mg/dL | 175.42 ± 39.74 | 203.02 ± 54.53 | 0.02 |
| Tg, mg/dL | 143.19 ± 61.70 | 165.51 ± 63.14 | 0.05 |
| HDL-c, mg/dL | 50.60 ± 16.68 | 42.98 ± 11.01 | 0.02 |
| LDL-c, mg/dL | 106.57 ± 30.28 | 103.49 ± 24.25 | 0.63 |
| VLDL-c, mg/dL | 28.72 ± 11.64 | 27.44 ± 12.97 | 0.66 |
| AIP: TC/HDL-c | 3.78 ± 1.34 | 5.11 ± 2.10 | 0.002 |
| Low risk, n (%) | 29 (78.4) | 20 (44.5) | |
| Moderate risk, n (%) | 7 (18.9) | 15 (33.3) | 0.006 |
| High risk, n (%) | 1 (2.7) | 10 (22.2) | |
| Serologic profile | |||
| ESR, mm/h | 21.74 ± 3.16 | 27.09 ± 4.96 | 0.07 |
| RF, IU/mL | 111.86 ± 331.47 | 136.74 ± 201.57 | 0.73 |
| CRP, mg/L | 3.75 ± 2.00 | 11.47 ± 7.92 | <0.001 |
| TNFα, pg/mL | 40.93 ± 3.14 | 66.78 ± 11.98 | 0.003 |
| IL-6, pg/mL | 20.92 ± 12.49 | 82.73 ± 29.87 | <0.001 |
| DMARDs | |||
| Methotrexate, n (%) | 31 (83.8) | 45 (100) | 0.04 |
| Chloroquine, n (%) | 22 (59.46) | 32 (71.1) | 0.22 |
| Sulfasalazine, n (%) | 9 (24.3) | 9 (20.0) | 0.79 |
| Azathioprine, n (%) | 6 (16.2) | 8 (17.8) | 1.00 |
| Corticosteroids, n (%) | 3 (8.1) | 2 (4.4) | 0.65 |
Anti-CCP, anticyclic citrullinated peptide antibodies; RA, rheumatoid arthritis; DAS28, disease activity score; TC, total cholesterol; Tg, triglycerides; HDL-c, high density lipoprotein cholesterol; LDL-c, low density lipoprotein cholesterol; VLDL-c, very low density lipoprotein cholesterol; AIP, atherogenic index of plasma; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; CRP, C-reactive protein; TNFα, tumor necrosis factor alpha; IL-6, interleukin-6; DMARDs, disease-modifying antirheumatic drugs.
Qualitative variables are expressed as frequencies (%); quantitative variables are expressed as means ± standard deviations (SD). Comparisons between proportions were computed using Chi-square or Fisher exact test. Comparisons between means were computed with unpaired Student's t-test.